Conference Diabetic Dyslipidemia 09.10.1398

Cholesterol Treatment Trialists Collaboration statin

Statin reduces the 5-year incidence of major coronary events, coronary revascularization, and stroke by about a fifth per mmol/L reduction in LDL, largely irrespective of initial lipid profile or other baseline characteristics

IMPROVE-IT ezetimabe

Adding a non-statin lipid-modifying agent in concert with a statin improves CV outcomes in addition to enhancing lipid lowering effects

The subset of patients with DM had a higher rate of major vascular events than patients without DM (46 vs. 31%)

 CV mortality, major CV event, or nonfatal stroke:

34.7% ( sim mono ) vs  32.7% (sim + Ezt) (HR 0.94 ;  P=0.016;  NNT 50)

FOURIER evolocumab

Evolocumab on a background statin therapy lowered LDL to a median of 30 mg /dL and reduced the risk of cardiovascular events

Patients with ASCVD benefit from the lowering of LDL below current targets

There were reductions of 21 to 27% in the risk of MI, stroke, coronary revascularization

NO effect on cardiovascular mortality.